Simcere Zaiming’s SIM0505 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced that it has...
Cancer
Huahai Pharmaceutical’s HB0028 and HB002.1T Cleared for Clinical Study by NMPA
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clearance...
Hengrui Pharmaceuticals Receives NMPA Approval for HRS-6768 Clinical Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical...
AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment
UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received a new indication approval...
NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients
The National Medical Products Administration (NMPA) in China has granted AstraZeneca (AZ, NASDAQ: AZN) and...
Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC
China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving an additional marketing approval from the...
Grand Pharmaceutical Initiates Study on GPN00289 for Liver Cancer Treatment
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the first patient enrollment in...
Shanghai Pharmaceuticals Halts Development of I001-B, I022, and C012 in the US
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) has declared the termination of clinical trials...
Astellas Pharma’s Vyloy Approved by NMPA for CLDN18.2 Positive Gastric Cancer
China’s National Medical Products Administration (NMPA) has indicated on its website that Japan-based Astellas Pharma...
HutchMed’s Orpathys Receives Priority Review for NSCLC Treatment in China
HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that the China National Medical Products...
Innovent Biologics Strikes Licensing Deal with Roche for IBI3009 ADC
China-based Innovent Biologics, Inc. (HKG: 1801) has announced a significant licensing agreement with Swiss pharmaceutical...
Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced a significant licensing agreement with US-based...
CARsgen Therapeutics’ Satricabtagene Autoleucel Shows Positive Results in Phase II Study
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced positive results from its pivotal Phase...
HitGen Inc. Initiates Phase II Clinical Trial for HG146 in Adenoid Cystic Carcinoma
China-based HitGen Inc. (SHA: 688222) has announced the commencement of the first patient enrollment in...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Achilles Therapeutics and AstraZeneca Seal $12 Billion Deal for TRACERx NSCLC Study Data
UK-based Achilles Therapeutics plc has announced a landmark deal worth USD 12 billion with AstraZeneca...
Shanghai Henlius Biotech Initiates Patient Dosing in Global Phase III ELAINE-3 Study for Lasofoxifene
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
Sino Biopharmaceutical Ltd. Files for Benmelstobart and Anlotinib Combination Therapy in ASPS Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) is poised to make another indication approval filing with...
MediLink Therapeutics’ YL201 Receives FDA Orphan Drug Designation for Small-Cell Lung Cancer
Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced that the US Food and...
FDA Approves Xcovery Holdings’ Ensartinib for Untreated ALK-Positive NSCLC Patients
On December 18, 2024, the Food and Drug Administration (FDA) granted approval for Betta Pharmaceutical...